Bryce Point Capital LLC Invests $495,000 in NeoGenomics, Inc. $NEO

Bryce Point Capital LLC acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 64,084 shares of the medical research company’s stock, valued at approximately $495,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Greenhouse Funds LLLP boosted its holdings in NeoGenomics by 57.8% in the second quarter. Greenhouse Funds LLLP now owns 7,431,147 shares of the medical research company’s stock worth $54,322,000 after purchasing an additional 2,722,823 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of NeoGenomics in the second quarter valued at about $6,071,000. First Light Asset Management LLC lifted its position in NeoGenomics by 13.3% in the second quarter. First Light Asset Management LLC now owns 6,846,432 shares of the medical research company’s stock worth $50,047,000 after purchasing an additional 803,610 shares during the period. Squarepoint Ops LLC increased its stake in NeoGenomics by 246.8% in the second quarter. Squarepoint Ops LLC now owns 735,473 shares of the medical research company’s stock valued at $5,376,000 after acquiring an additional 523,407 shares during the period. Finally, HighMark Wealth Management LLC boosted its holdings in NeoGenomics by 221.3% during the third quarter. HighMark Wealth Management LLC now owns 400,334 shares of the medical research company’s stock valued at $3,091,000 after purchasing an additional 275,734 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Insider Buying and Selling

In other news, EVP Alicia C. Olivo sold 20,916 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total value of $250,992.00. Following the transaction, the executive vice president owned 31,083 shares of the company’s stock, valued at $372,996. This represents a 40.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Warren Stone sold 22,128 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the transaction, the chief operating officer owned 121,631 shares of the company’s stock, valued at $1,520,387.50. The trade was a 15.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NEO shares. Leerink Partners set a $14.00 target price on shares of NeoGenomics in a research note on Tuesday, October 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, December 29th. Needham & Company LLC reissued a “buy” rating and issued a $14.00 price target on shares of NeoGenomics in a report on Monday, January 12th. Zacks Research raised NeoGenomics from a “hold” rating to a “strong-buy” rating in a report on Monday, January 12th. Finally, TD Cowen reiterated a “buy” rating on shares of NeoGenomics in a research note on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, NeoGenomics presently has an average rating of “Hold” and a consensus target price of $12.00.

NeoGenomics Trading Down 0.6%

Shares of NEO opened at $11.35 on Tuesday. The business’s 50-day moving average price is $12.24 and its 200-day moving average price is $9.86. The company has a quick ratio of 3.62, a current ratio of 3.91 and a debt-to-equity ratio of 0.41. The stock has a market cap of $1.47 billion, a PE ratio of -12.90 and a beta of 1.58. NeoGenomics, Inc. has a twelve month low of $4.72 and a twelve month high of $14.73.

NeoGenomics Company Profile

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.